Thrombogenics NV, of Leuven, Belgium, said the Scottish Medicines Consortium (SMC) issued a positive recommendation for the use of Jetrea (ocriplasmin) to treat adults with vitreomacular traction (VMT), including when associated with macular hole of diameter less than or equal to 400 microns.